Poziotinib治疗EGFR/HER2外显子20插入突变晚期NSCLC的扩展准入研究
本研究纳入30例EGFR/HER2外显子20插入突变的转移性非小细胞肺癌患者,接受Poziotinib(16 mg或更低)每日一次口服。主要终点ORR为30%,DCR为80%,中位PFS 5.6个月,中位OS 9.5个月。3级不良事件发生率高(66%),导致频繁减量和中断,可能影响PFS获益。
要点
- Poziotinib在EGFR/HER2外显子20插入突变mNSCLC中ORR 30%,DCR 80%。
- 中位PFS 5.6个月,中位OS 9.5个月。
- 3级不良事件66%,常见皮疹、腹泻、黏膜炎、甲沟炎。
核心结论
- Poziotinib在EGFR/HER2外显子20插入突变的mNSCLC患者中显示出抗肿瘤活性,但毒性较高导致频繁剂量调整。
研究设计与样本
- 扩展准入项目中的回顾性/前瞻性观察研究,纳入30例接受Poziotinib治疗的EGFR或HER2外显子20插入突变mNSCLC患者。
主要发现
- 中位年龄58岁(范围25-80岁),女性占73%,ECOG 0-1占83%,EGFR突变占73%,经治患者占83%。
- 73%的患者起始剂量为16 mg每日一次。
- 至数据截止,33例中22例(73%)出现疾病进展,30例中12例(40%)死亡。
- 中位PFS为5.6个月(95%CI 3.6-6.7),中位OS为9.5个月(95%CI 5.3-未达到)。
- ORR为30%(EGFR/HER2分别为23%和50%),DCR为80%。
关键数值与推荐
- 3级不良事件发生于66%的患者,包括皮疹(50%)、腹泻(17.6%)、黏膜炎(7%)和甲沟炎(3%)。
- 可能与肺炎相关的5级不良事件也有发生。
临床怎么用
- Poziotinib可作为EGFR/HER2外显子20插入突变mNSCLC的潜在靶向治疗选择,但需密切监测毒性并及时调整剂量。
- 高毒性导致的剂量中断和减量可能影响PFS获益,需权衡疗效与安全性。
局限性
- 样本量较小(30例),为扩展准入项目,非随机对照试验。
- 毒性发生率较高,可能导致剂量调整影响疗效评估。
- 需要进一步研究低剂量和新型给药方案(如每日两次)以优化获益风险比。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The treatment of metastatic non-small-cell lung cancer (mNSCLC) patients with EGFR/HER2 exon 20 insertion mutation (i-mut) remains an unmet clinical need. Poziotinib, a new generation tyrosine kinase inhibitor, is currently under investigation as a potential targeted therapy. This compassionate study of its use aims to describe the activity/toxicity of poziotinib in mNSCLC with EGFR/HER2-exon-20-i-mut. PATIENTS AND METHODS: NSCLC patients who were treated either with EGFR or HER2 exon 20-i-mut within an expanded access program were included in this study. Poziotinib (16 mg or less) was administrated orally quaque die (QD). The primary end-point was the overall response rate (ORR) assessed by central review using RECIST v1.1, and secondary end-points were median progression free survival (PFS), disease control rate (DCR), median overall survival (OS) and toxicity. RESULTS: The median age of all the 30 patients was 58 years (25-80 years), most of them were females (73%); ECOG 0-1 (83%), EGFR i-mut (73%) and pre-treated (83%). 73% started with poziotinib at a dose of 16 mg. At data cut-off, 22 of 33 patients (73%) experienced a progress in the disease and 12 of 30 (40%) died. Median PFS was 5.6 months (95% CI: 3.6-6.7 months) and the mOS 9.5 months (95% CI: 5.3 - not-reached months). The ORR was 30% (EGFR/HER2: 23/50%) and DCR 80%. G3 AEs were reported in 66% of the patients and were found with skin rash (50%), diarrhoea (17.6%), mucositis (7%) and paronychia (3%). G5, possibly associated with pneumonitis might also have occurred. CONCLUSIONS: Poziotinib exhibited effects in mNSCLC patients with EGFR/HER2-exon 20-i-mut. The toxicity rate was high leading to frequent dose interruption and reduction, thereby reducing mPFS in patients with good ORR/DCR. ZENITH20 trial is now being used to evaluate the low dose and new scheduled dose (e.g. bis in die (BID)).
引用
- Prelaj A, Bottiglieri A, Proto C, et al. Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program. Eur J Cancer. 2021. PMID: 33820681. doi:10.1016/j.ejca.2021.02.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。